Skin Cancer Evaluation. Simplified.

A handheld, objective device to assist primary care providers in checking patients for skin cancer in seconds.

DermaSensor™ Features

The Future Standard of Skin Care

  • Will provide an instant “High Risk” or “Low Risk” result using DermaSensor’s™ proprietary algorithm
  • Technology has a published sensitivity to skin cancer of 94% and 100% to melanoma13
  • Only ~20 seconds per skin lesion
  • Completely wireless, ergonomically designed and easy to hold
  • Always on, always ready when you need it

Intuitively Designed, Easy to Use

  • Intuitive on-screen interface guides you step by step through the evaluation
  • Works at any angle by using the side buttons or hand-held touch-screen

DermaSensor™ is NOT a camera nor a dermatoscope.

DermaSensor™ uses pulses of light and spectroscopy to assess lesions cellular and sub-cellular structure.

Non-Invasive Micron-Level Precision

  • Light-emitting tip gently and painlessly touches the surface of the skin and will evaluate information below the skin surface
  • Precision optics within the tip will capture cellular and sub-cellular pathological irregularities throughout a skin lesion as small as 2.5mm

Always By Your Side

  • The handheld unit charges wirelessly in the desktop base
  • Secure wireless connectivity allows you to expand use with DermaSensor™ companion software and other applications
  • DermaSensor’s™ small size fits on any desk

DermaSensor™ Use

1. Lesion Identification

Physician identifies the lesion of concern on their patient

2. DermaSensor™ Scan

Physician gently touches the small device tip to the lesion, taking instant recordings at different locations of the lesion

3. Photon Scattering

Light reflects and scatters from particles in the cells of the skin tissue back to DermaSensor’s™ spectral sensor

4. Algorithmic Analysis

The proprietary DermaSensor™ algorithm will analyze the reflected photons and provides an immediate “High Risk” or “Low Risk” result

DermaSensor™ Technology

  • DermaSensor’s™ tip reflects and records quick bursts of light off the lesion’s cellular and sub-cellular content.
  • The light will be analyzed by the built-in computer to provide information to help physicians assess skin lesions (including melanomas, squamous cell carcinomas, and basal cell carcinomas) to aid in a referral decision.
  • By examining the difference in light scattering, DermaSensor™ will determine if the skin lesion is “High Risk” or “Low Risk,” an immediate output.
  • Elastic Scattering Spectroscopy (ESS) has been validated in 30+ publications on clinical studies that demonstrate its ability to distinguish malignant tissue from benign tissue, including in skin. In multiple studies, ESS has been shown to provide information that is comparable to histopathologic assessment in the analysis of cellular microscopic structure. 1 2 3 13

About ESS

DermaSensor™ uses Elastic Scattering Spectroscopy (ESS), a process that evaluates how photons scatter when reflected off of different cellular structures. Malignant lesions have been reported to have different cellular and sub-cellular structures than benign lesions, scattering light differently.

DermaSensor™ for Physicians

Each year ~5,500,000 skin cancers are diagnosed in America making skin cancer more common than all other cancers combined4. Unfortunately, only 15% of Americans receive an annual skin check5 and, even with that low rate, the average wait time for a dermatologist is still 32.3 days6.

While the 5-year survival rate is 92-97% for Stage I melanoma, it is only 15% for Stage IV melanoma7. In addition, the total treatment costs for melanoma in situ is ~$4,648 while Stage IV melanoma is ~$159,8088.

Effective evaluation of patients with potential skin cancer in primary care is hampered by limited consultation time and limited dermatology training. PCPs will be able to use DermaSensor™ as an adjunctive tool to better assess skin lesions and determine whether their patients need additional clinical care.

What is an Adjunctive Tool?

An adjunctive tool, also known as a clinical decision support tool, is not meant to replace clinicians’ decision-making. DermaSensor™ will provide clinicians with additional information about a lesion for them to consider in their referral decision. An adjunctive tool is not a diagnostic, so will not provide information regarding whether or not cancer is present, or the exact type of potential skin cancer (e.g. melanoma), nor does it make any decision for the clinician.

DermaSensor™ is NOT a camera nor a dermatoscope.

DermaSensor™ uses pulses of light and spectroscopy to assess lesions cellular and sub-cellular structure.

DermaSensor™ Benefits

DermaSensor™ will quickly assess information below the skin surface, giving physicians greater confidence and performance in their decision-making.

DermaSensor™ could improve early detection of skin cancer and reduce the number of unnecessary referrals.

Patients will view DermaSensor™ as a supplemental and valuable addition to the skin care they already receive from physicians.

The non-invasive nature of DermaSensor™ is expected to be unintimidating to patients and reassure them that they are receiving high-quality care.

The machine-learning algorithm is derived from thousands of samples of pathologically-verified lesions and is professionally trained by expert data scientists.

Why PCPs Care About Skin Cancer In Their Practice

1 in 5 Americans are diagnosed with skin cancer in their lifetime. 4

Annual cost of treating skin cancers in the U.S. is estimated at $8.1 billion, with an estimated 5.4 million new cases of skin cancer each year.9 10

36.5% of patients present with at least one skin condition to their primary care physician. 11

Primary Care Physicians refer as few as 54% of the cancerous lesions they evaluate. 12

Contact Us

As Seen On